---
canonical_name: Punarnava
alternate_names: Boerhavia diffusa, Boerhaavia diffusa, Red Spiderling, Spreading Hogweed, Tarvine, Raktapunarnava
canonical_topic: Punarnava for Health & Longevity
short_topic_lc: punarnava
creation_date: 2026-0825-2139
creator_ai_fullname: Opus 5
ep_keywords: Ayurvedic Herbs, Herbal Diuretics
---

# Punarnava for Health & Longevity
<section id="top" markdown="1"></section>
Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5

**Also known as:** *Boerhavia diffusa*, *Boerhaavia diffusa*, Red Spiderling, Spreading Hogweed, Tarvine, Raktapunarnava
  
## Motivation

<!-- Author's statement: This Motivation section was written last, after every other section of this review had been completed, so that it reflects the full scope of the evidence surveyed rather than an opening impression. -->

Punarnava (*Boerhavia diffusa*) is a sprawling weed that grows through much of India, Africa and the tropical Americas, where its thick root has been dried and taken as medicine for well over two thousand years. Its Sanskrit name means "renewer" — a reference to the way the plant appears to die back in the dry season and revive with the rains, and to the classical claim that it renews the body. It is best known as a mild herb for shedding excess body fluid and easing swelling, and as a support for the kidneys and liver.

Punarnava is one of the most widely traded medicinal plants in India and appears in dozens of traditional multi-herb formulas, several of which are still dispensed in Indian hospitals today. Interest outside its traditional setting comes mainly from laboratory work on its distinctive root compounds, which appear to calm inflammation and shield kidney and liver tissue in animals.

This review examines what is known and not known about punarnava: what its active compounds do, which claimed effects rest on human evidence rather than animal work, what safety and product-quality questions surround it, and how it is dosed and monitored in practice.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**
  
## Recommended Reading

Sources that give a substantive, high-level overview of punarnava's chemistry, traditional use, and pharmacology.

<!-- Author's statement on the search: On 20 August 2026 a real-time search was run for high-level overview content on Punarnava / Boerhavia diffusa. Each priority platform was searched by name paired with the intervention (web search plus the site's own search where available): foundmyfitness.com (Rhonda Patrick), peterattiamd.com (Peter Attia), hubermanlab.com (Andrew Huberman), chriskresser.com (Chris Kresser), lifeextension.com (Life Extension Magazine), and lifespan.io. None of the six has published any content that names Punarnava or Boerhavia diffusa. General web and PubMed searches were then used to identify qualifying narrative reviews, editorials, and primary research; systematic reviews and meta-analyses were excluded and routed to the Systematic Reviews section, and Grokipedia, Examine and ConsumerLab were excluded as they have dedicated sections below. -->

* [A comprehensive review of the phytochemistry, pharmacology, pharmacokinetics, and green nanotechnological significance of Boerhavia diffusa Linn.](https://pubmed.ncbi.nlm.nih.gov/40334820/) - Patel et al., 2025

  The most current single-source map of the plant's chemistry and pharmacology, and unusual in devoting space to the low oral bioavailability that limits every claimed effect.

* [Ethnomedicinal values of Boerhaavia diffusa L. as a panacea against multiple human ailments: a state of art review](https://pubmed.ncbi.nlm.nih.gov/38033469/) - Das et al., 2023

  Connects each named constituent to the traditional indication it is meant to explain, which makes it the best starting point for judging where mechanism and folklore actually meet.

* [Phytochemical, therapeutic, and ethnopharmacological overview for a traditionally important herb: Boerhavia diffusa Linn.](https://pubmed.ncbi.nlm.nih.gov/24949473/) - Mishra et al., 2014

  Organises the pharmacology by organ system and is candid that many underlying studies lack validated methods, making it a useful counterweight to more enthusiastic summaries.

* [Ethnomedicinal uses, phytochemistry and pharmacological properties of the genus Boerhavia](https://pubmed.ncbi.nlm.nih.gov/26844923/) - Patil & Bhalsing, 2016

  Covers the whole *Boerhavia* genus, of which *B. diffusa* supplies 131 of the 180 catalogued compounds, and flags the missing doses, durations, and controls in the underlying studies.

* [The Pharmacology and Therapeutics of Bœrhaavia Diffusa (Punarnava)](https://pubmed.ncbi.nlm.nih.gov/29007842/) - Chopra et al., 1923

  The founding pharmacological evaluation of this herb, from the School of Tropical Medicine, Calcutta; still the primary source behind most modern statements that punarnava is a diuretic.

Note on coverage: none of the six priority platforms (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has published anything on punarnava, so none could be included. Punarnava sits outside the Western longevity-supplement conversation these platforms cover, and the accessible high-quality writing on it is almost entirely in the ethnopharmacology literature.
  
## Grokipedia

<!-- Author's statement on the search: On 20 August 2026 grokipedia.com was searched directly using the browser tool for "Boerhavia diffusa" (62 results returned). A dedicated primary article exists at /page/Boerhavia_diffusa and was opened and confirmed. -->

[Boerhavia diffusa](https://grokipedia.com/page/Boerhavia_diffusa)

The dedicated article covers botany, distribution, phytochemistry and medicinal claims in one place, and is more restrained about efficacy than the herbal-marketing pages that dominate search results for this plant.
  
## Examine

<!-- Author's statement on the search: On 20 August 2026 examine.com was searched directly for "punarnava". The search returned one intervention entry, and the dedicated supplement page at /supplements/punarnava/ was opened and confirmed. -->

[Punarnava](https://examine.com/supplements/punarnava/)

Examine states plainly that no human studies of *Boerhaavia diffusa* have been conducted, then derives a human-equivalent dose range from rodent work — the single most useful sanity check available on dosing.
  
## ConsumerLab

<!-- Author's statement on the search: On 20 August 2026 consumerlab.com was searched directly for both "punarnava" and "boerhavia". Both searches returned "Sorry, we didn't find any results", and no product review, clinical update, CL Answer, or recall entry exists for this herb. -->

No ConsumerLab article, product review, or test report for Punarnava exists as of 20 August 2026. ConsumerLab has not tested single-herb Ayurvedic root powders, so no independent purity or label-accuracy data are available.
  
## Systematic Reviews

The one systematic review indexed on PubMed for this herb, covering its constituents and the analytical methods used to verify product identity.

<!-- Author's statement on the search: On 20 August 2026 PubMed was searched in real time with (Boerhavia diffusa OR Boerhaavia diffusa OR Punarnava) AND (systematic review[Title/Abstract] OR meta-analysis[Title/Abstract] OR systematic review[Publication Type] OR meta-analysis[Publication Type]), returning a single record. Broader searches (190 records for the herb overall, 46 for safety and toxicity terms, 11 for clinical-trial terms) confirmed that no meta-analysis and no second systematic review exists. Selection was therefore trivial; the single qualifying paper is listed. -->

* [Boerhavia diffusa L.: Integrative Traditional Uses, Phytochemistry, Pharmacological Properties, and Quality Control/Quality Assurance](https://pubmed.ncbi.nlm.nih.gov/41355611/) - Kumar & Singh, 2026

  Systematically screened 1979–2025 literature, catalogued 132 constituents, and set out the chromatographic markers used to verify that a product is genuine punarnava.

Trade-off coverage: the claimed benefit side of punarnava has exactly one systematic review, listed above. The principal risk side — adverse events, toxicity, and herb-drug interaction — is unrepresented: no systematic review or meta-analysis of punarnava safety has been published, so the risk section below rests on primary studies, case reports, and product-contamination surveys of Ayurvedic medicines generally.
  
## Mechanism of Action

Punarnava's root is a mixture, not a single drug. Its main constituents are rotenoids (boeravinones A–J), the alkaloid punarnavine, the flavonoid glycoside eupalitin 3-O-β-D-galactopyranoside, the lignan liriodendrin, and the steroid β-ecdysone.

Three mechanisms recur. First, blockade of the cyclo-oxygenase enzymes COX-1 and COX-2 (which make inflammatory signalling molecules and are the targets of ibuprofen): [purified rotenoids inhibit both](https://pubmed.ncbi.nlm.nih.gov/23914900/) at half-maximal inhibitory concentrations (IC50 — the amount that halves enzyme activity) near 22 and 26 micromolar. Second, antioxidant defence: [boeravinone G quenches hydroxyl radicals at nanomolar concentrations](https://pubmed.ncbi.nlm.nih.gov/21625488/) and damps NF-κB (nuclear factor kappa B, a master switch for inflammatory genes), while extract [drives Nrf2](https://pubmed.ncbi.nlm.nih.gov/28068633/) (a control protein that switches on the cell's antioxidant genes) into the nucleus. Third, kidney-tubule signalling: [boeravinone C activates PPAR-α](https://pubmed.ncbi.nlm.nih.gov/39880066/) (peroxisome proliferator-activated receptor alpha, which governs fat burning), and extract [restores nephrin](https://pubmed.ncbi.nlm.nih.gov/38741412/), a protein of the kidney's filter.

The diuretic action is least explained; candidates include [inhibition of angiotensin-converting enzyme](https://pubmed.ncbi.nlm.nih.gov/23591029/) (ACE, which makes the body's main blood-pressure-raising hormone) and [calcium-channel blockade by liriodendrin](https://pubmed.ncbi.nlm.nih.gov/19948752/).

A competing reading deserves equal weight: boeravinones are close relatives of rotenone, a mitochondrial poison used to model Parkinson's disease. The chemistry credited with benefit belongs to a family toxicologists watch closely; no study has separated the possibilities.

Pharmacology is thinly defined. No human dataset exists; in rats [boeravinone B peaks near 40 ng/mL](https://pubmed.ncbi.nlm.nih.gov/25864706/), indicating poor absorption and no tissue selectivity. Metabolism is hepatic, and extract [inhibits CYP1A2, CYP2D6 and CYP3A4](https://pubmed.ncbi.nlm.nih.gov/28942133/), the enzymes clearing most prescription drugs. No human half-life exists.
  
## Historical Context & Evolution

Punarnava enters the written record in the classical Ayurvedic compendia, where the root is classed as a *rasayana* (a rejuvenative) and as *shothahara* — an agent against swelling. Its original indications were oedema and dropsy, jaundice, anaemia, and urinary complaints, and it became a component of more than thirty named formulas, including Punarnava Mandura, Punarnavadi Kwath and Punarnavashtak Kwath.

The plant's modern career began in 1923, when [Chopra and colleagues at the School of Tropical Medicine, Calcutta](https://pubmed.ncbi.nlm.nih.gov/29007842/) subjected it to pharmacological and clinical evaluation — one of the earliest Western-style investigations of any Ayurvedic drug. Their report of diuretic action in patients with fluid overload is still the source most modern summaries ultimately rest on. Pharmacognostic work in the 1940s established how to tell true punarnava from the look-alike *Trianthema portulacastrum*, and [further pharmacological screening followed in the 1970s](https://pubmed.ncbi.nlm.nih.gov/1178789/).

Attention then shifted from whole-plant diuresis to organ protection, after [an alcoholic whole-plant extract was shown to protect rodent liver against carbon tetrachloride](https://pubmed.ncbi.nlm.nih.gov/2056758/) and to increase bile flow, and to isolated constituents as drug leads.

That reorientation was not a verdict on the older claim. The diuretic indication was never tested and found wanting in a modern controlled trial; it was simply never tested that way at all, and the field moved to targets that suited contemporary funding and publication. What changed was the questions being asked, not the answers.
  
## Expected Benefits

<!-- Author's statement on the search: Before writing this section a dedicated benefit-profile search was performed on 20 August 2026 across PubMed (190 records for the herb; targeted searches for diuretic, nephroprotective, hepatoprotective, antidiabetic, immunomodulatory, antihypertensive, anti-inflammatory, antioxidant, anticonvulsant, antimicrobial, antiviral, wound-healing, urolithiasis and clinical-trial terms), ClinicalTrials.gov, Examine.com, Grokipedia, and general web search, to confirm that no major claimed benefit has been omitted. -->

No benefit of punarnava reaches a High level of evidence: after a century of study, no adequately powered, blinded, randomised controlled trial (RCT — a study in which participants are assigned by chance to treatment or control) of the single herb has been published.

### Medium 🟩 🟩

#### Kidney Function Support in Chronic Kidney Disease

Punarnava root shields kidney tissue against chemical injury with unusual consistency across independent laboratories and unrelated insults, plausibly through antioxidant and anti-inflammatory signalling and preservation of the filtration barrier. The rodent evidence spans [cisplatin](https://pubmed.ncbi.nlm.nih.gov/27667768/), [gentamicin](https://pubmed.ncbi.nlm.nih.gov/26166999/), [adenine](https://pubmed.ncbi.nlm.nih.gov/38741412/) and [methotrexate](https://pubmed.ncbi.nlm.nih.gov/42046059/) models. Human data exist but are weak: uncontrolled multi-herb Ayurvedic protocols and [one small unblinded comparison against enalapril](https://pubmed.ncbi.nlm.nih.gov/23723672/), both from Ayurvedic institutions with an institutional stake in the result.

**Magnitude:** In rats, root extract at 200 mg/kg significantly blunted cisplatin-driven rises in serum creatinine and blood urea nitrogen (p < 0.001); in the only comparative human study, an Ayurvedic enema protocol reported 79.6% versus 33.3% improvement on a composite symptom-and-laboratory score against enalapril 5 mg twice daily over 30 days — an unblinded, non-standard endpoint that cannot be converted to a change in kidney filtration rate.

### Low 🟩

#### Diuretic and Anti-Edema Effect

The oldest and most consistently repeated claim: increased urine volume with sodium and chloride excretion, without the potassium loss typical of loop diuretics. Support comes from [early clinical pharmacology in patients with fluid overload](https://pubmed.ncbi.nlm.nih.gov/29007842/) and [later animal screening](https://pubmed.ncbi.nlm.nih.gov/1178789/). No modern controlled human trial has measured urine output on punarnava.

**Magnitude:** Direction is consistent — increased urine flow, most evident where fluid retention already exists rather than in people whose fluid balance is normal — but the literature reports no outcome figure, because no controlled study has quantified urine volume or sodium excretion in humans.

#### Liver Protection Against Chemical Injury

Root extract reduces liver enzyme leakage and histological damage in rodents given hepatotoxins, and increases bile flow. Evidence comes from [carbon tetrachloride models](https://pubmed.ncbi.nlm.nih.gov/2056758/), [a thioacetamide model](https://pubmed.ncbi.nlm.nih.gov/9147255/), and [an oxaliplatin model](https://pubmed.ncbi.nlm.nih.gov/31813854/). No human liver-function trial of the isolated herb exists.

**Magnitude:** Direction is protective and dose-dependent in rodents pre-treated before the toxin, with no signal for reversing established damage; the literature reports no human outcome figure.

#### Blood Glucose Lowering

Aqueous leaf extract lowers fasting glucose, raises insulin, and normalises liver glucose-handling enzymes in chemically diabetic rats, with effects reported as at least equal to standard oral agents. Shown in [alloxan-diabetic rats](https://pubmed.ncbi.nlm.nih.gov/15036478/) and [replicated with a renoprotective endpoint](https://pubmed.ncbi.nlm.nih.gov/22754925/). No human glucose data exist.

**Magnitude:** 200 mg/kg daily for four weeks significantly reduced blood glucose and glycated haemoglobin in diabetic rats, with the effect described as more prominent than glibenclamide at 600 µg/kg.

#### Anti-Inflammatory Activity

The rotenoid fraction inhibits both cyclo-oxygenase enzymes and reduces paw swelling in the standard rodent inflammation model, at a level comparable to an over-the-counter anti-inflammatory. Demonstrated for [isolated boeravinones](https://pubmed.ncbi.nlm.nih.gov/23914900/) and for [a phospholipid-complexed rotenoid fraction](https://pubmed.ncbi.nlm.nih.gov/25864706/). No human inflammatory-marker data exist.

**Magnitude:** Boeravinone B at 50 mg/kg reduced carrageenan-induced rat paw oedema by 56.6%; the phospholipid complex achieved 64% inhibition at five hours versus 50% for ibuprofen.

#### Support in Iron-Deficiency Anaemia via Mandura Formulations

Punarnava Mandura — punarnava with a processed iron calx — improved symptoms in an uncontrolled Ayurvedic study of [geriatric anaemia](https://pubmed.ncbi.nlm.nih.gov/26664234/), and [laboratory work on a related punarnava-iron preparation](https://pubmed.ncbi.nlm.nih.gov/42238151/) shows the processing raises absorbable iron. The effect is most plausibly the iron, not the herb; no arm isolated punarnava alone.

**Magnitude:** In 40 completers taking two 250 mg tablets twice daily for 90 days, 30% showed moderate and 70% mild improvement on a composite Ayurvedic symptom scale; no haemoglobin change attributable to the herb rather than the iron has been isolated.

#### Anti-Tumour and Anti-Metastatic Activity

Extracts and the alkaloid punarnavine inhibit cancer cell growth in culture and suppress tumour spread in rodents, apparently by blocking matrix metalloproteinases (enzymes tumours use to invade tissue) and new blood-vessel growth. Shown for [B16F10 melanoma metastasis](https://pubmed.ncbi.nlm.nih.gov/15670614/) and a [4T1 breast tumour model](https://pubmed.ncbi.nlm.nih.gov/29770894/). No human data exist.

**Magnitude:** Prophylactic extract dosing inhibited lung metastasis formation by about 95% in melanoma-bearing mice and more than doubled survival; punarnavine at 40 mg/kg significantly reduced primary breast tumour growth and spread to lymph nodes, lungs and liver in the 4T1 model.

### Speculative 🟨

#### Blood Pressure and Cardiac Remodelling

An isolated flavonoid glycoside lowered blood pressure in steroid-hypertensive rats, and extract reduced angiotensin-driven heart-muscle thickening in cells and rats. Basis is mechanistic and preclinical only; no human blood-pressure study exists.

#### Reduced Calcium-Oxalate Stone Formation

Extract shrank calcium oxalate crystals in a test tube and shifted them toward the less injurious dihydrate form; [one rat model of excess urinary oxalate](https://pubmed.ncbi.nlm.nih.gov/21846174/) reduced crystal deposition. No human stone-recurrence data exist.

#### Relief of Benign Prostatic Enlargement

Root extract limited testosterone-driven prostate growth in rats and relaxed isolated prostatic smooth muscle without altering testosterone. Basis is a single animal study with no human urinary-symptom data.

#### Reduced Weight Gain on a High-Fat Diet

Extract limited weight gain and fat accumulation in rats fed a high-fat diet, apparently by blocking cannabinoid receptors. Basis is a single animal study; no human weight or metabolic data exist.

#### Anticonvulsant Activity

The liriodendrin-rich root fraction protected rats against chemically induced seizures, consistent with the calcium-channel blockade described in the mechanism section. Basis is one rodent model; no human neurological data exist.

#### Antimicrobial and Antiviral Activity

A root dehydrorotenoid blocks hepatitis C virus entry into liver cells, and extract suppresses *Mycobacterium tuberculosis*-driven inflammation. Basis is cell-culture work only; no animal infection model or human data exist.
  
## Benefit-Modifying Factors

* **Drug-metabolising enzyme genotype:** Because the extract inhibits CYP2D6 and CYP3A4, people who are genetically slow metabolisers at these enzymes may accumulate co-administered drugs faster. No punarnava-specific pharmacogenetic study exists; the inference is from the in-vitro inhibition profile.

* **Baseline biomarker levels:** Every claimed benefit is measured against an abnormal baseline. Diuresis is visible where fluid is retained; kidney and liver protection is measured against induced injury; glucose lowering was shown in diabetic, not normal, animals. Normal baselines should be expected to move less.

* **Sex-based differences:** No study has reported sex-stratified outcomes. One in-vitro finding is sex-relevant: methanolic extract [competes with oestradiol at the oestrogen receptor and suppresses an oestrogen-responsive gene](https://pubmed.ncbi.nlm.nih.gov/19723573/), so effects in oestrogen-sensitive tissue may differ by sex and menopausal status.

* **Pre-existing health conditions:** Advanced kidney disease, cirrhosis, and diabetes are the conditions in which the strongest animal signals were generated, and also those in which fluid, electrolyte and drug-clearance changes carry the most consequence. Benefit and hazard scale together in these groups.

* **Age:** Older adults have less kidney reserve, blunted thirst, and more concurrent prescriptions. The same diuretic effect that relieves swelling at 45 can produce volume depletion and drug accumulation at 75, so the benefit-to-harm ratio narrows with age.
  
## Potential Risks & Side Effects

<!-- Author's statement on the search: Before writing this section a dedicated side-effect-profile search was performed on 20 August 2026 across PubMed (46 records for Boerhavia diffusa combined with toxicity, safety, adverse, LD50, abortifacient, estrogenic and heavy-metal terms; plus targeted searches on CYP inhibition, genotoxicity and teratogenicity), the published case-report literature, drug-reference and consumer drug-information sources reachable by web search, and Examine.com, to confirm that no major risk has been omitted. Because punarnava is not a prescription drug, no manufacturer prescribing information exists. -->

### High 🟥 🟥 🟥

#### Heavy Metal Contamination of Ayurvedic Products

The best-documented hazard attaches to the product category, not the plant. Lead, mercury and arsenic are recurrent contaminants of Ayurvedic preparations, arising from adulteration, deliberate metal-calx ingredients such as the *mandura* in Punarnava Mandura, and poor manufacturing control. Evidence comes from [a public-health lead-poisoning cluster investigation that assayed 252 products](https://pubmed.ncbi.nlm.nih.gov/29528276/) and [a systematic scoping review of 220 published poisoning cases](https://pubmed.ncbi.nlm.nih.gov/34142855/). Punarnava-containing formulas are not exempt.

**Magnitude:** Lead was detected in 65% of 252 Ayurvedic product samples, mercury in 38%, arsenic in 32%; among positive samples, 36–49% exceeded recommended daily intake limits for pharmaceutical impurities, some by several thousand-fold. Across the published case series, 83.7% of analysed drug samples exceeded permissible heavy-metal content.

### Medium 🟥 🟥

#### Inhibition of Drug-Clearing Liver Enzymes

Crude aqueous extract inhibits three of the enzymes that metabolise most prescription medicines, both reversibly and in the time-dependent fashion that predicts a sustained interaction rather than a transient one. This is [demonstrated with recombinant human enzymes](https://pubmed.ncbi.nlm.nih.gov/28942133/), and the authors modelled clinically meaningful interaction risk from the observed potencies. The practical consequence is elevated blood levels of co-administered drugs, which matters most for medicines with a narrow safety margin.

**Magnitude:** Half-maximal inhibition occurred at 7.36 µg/mL for CYP3A4, 9.48 µg/mL for CYP1A2, and 17.79 µg/mL for CYP2D6, with time-dependent inhibition of all three — potencies in the range at which herbal extracts have produced documented clinical interactions.

#### Unpredictable Potency from Adulteration and Batch Variability

Two distinct problems compound: the plant is routinely substituted with *Trianthema portulacastrum* and related species, and even authentic material varies enormously in marker content. [Genetic barcoding was developed specifically to separate punarnava from its adulterants](https://pubmed.ncbi.nlm.nih.gov/23317705/), and [chromatographic fingerprinting of wild and market samples across India](https://pubmed.ncbi.nlm.nih.gov/42077207/) classified several commercial samples as non-authentic. A dose that works from one batch may do nothing, or considerably more, from the next.

**Magnitude:** Across 21 wild and market samples, boeravinone B ranged from 0.016 to 5.52 µg/mg — a roughly 345-fold spread — and β-ecdysone from 0.76 to 12.64 µg/mg, a roughly 17-fold spread.

### Low 🟥

#### Drug-Induced Liver Injury from Mandura Formulations

Punarnava Mandura has been implicated in acute liver injury, [documented in a formal causality-assessed case report](https://pubmed.ncbi.nlm.nih.gov/29152040/). A preparation taken for liver support produced hepatotoxicity. Whether the herb, the iron calx, a contaminant, or a co-administered formula was responsible was not resolved; injury reversed on withdrawal.

**Magnitude:** Not quantified in available studies. Only a single causality-assessed case report exists, and no cohort or pharmacovigilance denominator has been published from which an incidence could be calculated.

#### Cutaneous Allergic Reactions

Skin rash attributed to Punarnava Mandura has been reported, with the attribution strengthened by the patient tolerating all other co-administered medicines on rechallenge while omitting this one. Described in [a pharmacovigilance case report from a national traditional-medicine institute](https://pubmed.ncbi.nlm.nih.gov/38716496/). Reaction resolved on withdrawal with antihistamine treatment.

**Magnitude:** Not quantified in available studies. The literature contains one case confirmed by resolution on stopping the drug, and no systematic adverse-event surveillance, so no rate can be derived.

#### Suppression of Immune Cell Activity ⚠️ Conflicted

Ethanolic root extract suppressed human immune-cell function in vitro, [inhibiting natural killer cell killing, interleukin-2 and TNF-α](https://pubmed.ncbi.nlm.nih.gov/12188040/) (tumour necrosis factor alpha, an inflammatory messenger). The opposite appeared in tumour-bearing mice, where [punarnavine raised interleukin-2](https://pubmed.ncbi.nlm.nih.gov/18075866/). Direction may depend on species, preparation, and prior immune activation.

**Magnitude:** Direction in human cells is suppressive, and appears at extract concentrations achievable in culture but of unknown relevance to oral dosing; the literature reports no outcome figure, since no human study has measured immune function on punarnava.

#### Fluid and Electrolyte Depletion with Sustained Diuresis

The herb's signature effect is also its most predictable hazard. Sustained increases in urine and sodium output, [described since the earliest pharmacological work](https://pubmed.ncbi.nlm.nih.gov/29007842/), can cause volume depletion, dizziness on standing, and low sodium — especially in older adults and alongside prescription diuretics.

**Magnitude:** Not quantified in available studies. No controlled human trial has measured serum sodium, potassium or body weight on punarnava, so the extent of depletion at any given dose is unknown.

### Speculative 🟨

#### Mitochondrial Toxicity from Rotenoid Chemistry

Boeravinones share the rotenoid skeleton of rotenone, a mitochondrial poison used to model Parkinson's disease. Basis is chemical class alone; no study has tested boeravinones at achievable human exposures.

#### Gastrointestinal Intolerance at High Doses

Nausea, cramping and loose stools are reported by traditional and consumer sources at root-powder doses above roughly 5 g daily. Basis is anecdotal and practitioner report; no controlled tolerability study exists.

#### Interference with Oestrogen-Dependent Signalling

Methanolic extract competed with oestradiol for receptor binding and suppressed an oestrogen-responsive gene in breast cancer cells. Basis is in-vitro only, with no evidence that oral dosing produces such concentrations in tissue.

#### Adverse Effects in Pregnancy

Traditional texts caution against use beyond early pregnancy on grounds of uterine stimulation, while a rat study at 250 mg/kg throughout gestation found no birth defects. Basis is one animal study against traditional caution.
  
## Risk-Modifying Factors

* **Drug-metabolising enzyme genotype:** CYP2D6 and CYP3A4 poor metabolisers start with less clearance capacity, so enzyme inhibition by the extract has proportionally more effect. No punarnava-specific pharmacogenetic data exist; the concern is inferred from the measured inhibition profile.

* **Baseline biomarker levels:** Low-normal baseline sodium, low blood pressure, or an already reduced filtration rate leave little margin before diuresis becomes clinically visible. Elevated baseline liver enzymes make any new hepatotoxic signal harder to attribute and more consequential.

* **Sex-based differences:** No sex-stratified safety data exist. The [in-vitro anti-oestrogenic activity](https://pubmed.ncbi.nlm.nih.gov/19723573/) means the theoretical hazard profile differs between women — particularly those with oestrogen-sensitive conditions or on hormone therapy — and men, but this has not been tested in either.

* **Pre-existing health conditions:** Kidney impairment, cirrhosis, heart failure on diuretics, low blood pressure and iron overload each amplify a specific hazard. Anyone on a narrow-margin medicine cleared by CYP3A4 carries the enzyme-inhibition risk regardless of other conditions.

* **Age:** Older adults combine reduced kidney reserve, blunted thirst, more medications, and higher susceptibility to falls after a drop in standing blood pressure. The heavy-metal risk also accumulates over years of use, disproportionately affecting long-term older users.
  
## Key Interactions & Contraindications

* **Loop and thiazide diuretics (furosemide, torsemide, hydrochlorothiazide, indapamide):** Caution. Additive diuresis, with volume depletion, low sodium and orthostatic dizziness (light-headedness on standing up). Mitigation: separate initiation by at least two weeks, weigh daily, and check electrolytes at two weeks.

* **CYP3A4 substrates with a narrow safety margin (tacrolimus, ciclosporin, sirolimus, apixaban, amiodarone, simvastatin):** Absolute contraindication for transplant immunosuppressants; caution otherwise. Consequence: drug accumulation, from statin muscle injury to graft toxicity. Mitigation: avoid, or monitor drug levels.

* **CYP2D6 substrates (metoprolol, flecainide, tamoxifen, codeine, tricyclic antidepressants):** Caution. Consequence: exaggerated beta-blockade or arrhythmia risk; with tamoxifen and codeine, reduced activation and lost efficacy. Mitigation: avoid the combination where a therapeutic alternative exists.

* **CYP1A2 substrates (theophylline, clozapine, olanzapine, tizanidine):** Caution. Consequence: raised blood levels, with seizure and sedation risk for clozapine and theophylline. Mitigation: avoid concurrent use, or monitor blood levels and clinical response.

* **Lithium:** Absolute contraindication without supervision. Consequence: diuretic-induced sodium loss raises lithium reabsorption and can precipitate toxicity. Mitigation: do not combine outside a monitored setting with lithium level checks.

* **Glucose-lowering drugs (metformin, sulfonylureas, insulin, SGLT2 inhibitors — a class that clears glucose through the urine):** Caution. Consequence: additive hypoglycaemia and, with SGLT2 inhibitors, additive fluid loss. Mitigation: monitor glucose more frequently in the first month.

* **Antihypertensives (ACE inhibitors — ramipril, lisinopril; angiotensin receptor blockers — losartan; calcium channel blockers — amlodipine):** Caution. Consequence: additive blood pressure lowering and dizziness on standing. Mitigation: check standing and seated blood pressure weekly during the first month of combined use.

* **Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs, common painkillers: ibuprofen, naproxen, diclofenac):** Caution. Consequence: they blunt diuresis and, combined with volume depletion, raise acute kidney injury risk. Mitigation: maintain fluid intake and avoid regular NSAID use while taking punarnava.

* **Over-the-counter antacids and iron:** Caution with mandura-type formulations. Consequence: antacids and proton pump inhibitors (stomach-acid blockers such as omeprazole) reduce iron absorption; unmonitored iron-containing formulas risk overload. Mitigation: separate by two hours and check ferritin.

* **Supplements with additive diuretic or fluid-shifting action (dandelion leaf, juniper, horsetail, uva ursi, caffeine, gokshura):** Caution. Consequence: compounded fluid and electrolyte loss. Mitigation: use only one diuretic botanical at a time and track body weight.

* **Supplements with additive glucose-lowering action (berberine, cinnamon, gymnema, alpha-lipoic acid, chromium):** Caution. Consequence: additive hypoglycaemia, particularly when fasted or training. Mitigation: introduce one agent at a time with glucose monitoring.

* **Other CYP-inhibiting botanicals (grapefruit juice, goldenseal, black pepper piperine extracts):** Caution. Consequence: compounded enzyme inhibition and unpredictable drug levels. Mitigation: avoid stacking punarnava with other known enzyme-inhibiting botanicals.

* **Bhasma and mandura-containing Ayurvedic formulas:** Absolute contraindication without certified metal testing. Consequence: cumulative lead, mercury or arsenic exposure. Mitigation: use single-herb root powder or extract with a batch certificate of analysis instead.

**Populations who should avoid Punarnava:**

* Solid-organ transplant recipients on calcineurin inhibitors (anti-rejection drugs: tacrolimus, ciclosporin), at any time post-transplant
* Pregnancy beyond the first trimester, and lactation
* Chronic kidney disease stage 4 or 5 (estimated filtration rate below 30 mL/min/1.73 m²) outside supervised care
* Decompensated cirrhosis (Child-Pugh Class B or C) or any unexplained elevation of liver enzymes above three times the upper limit of normal
* Anyone taking lithium, clozapine, or theophylline
* Hereditary haemochromatosis (an inherited condition causing iron overload) or serum ferritin above 300 ng/mL, for mandura-containing formulations
* Symptomatic low blood pressure (seated systolic below 100 mmHg) or recurrent fainting on standing
  
## Risk Mitigation Strategies

* **Batch certificate of analysis rather than label claim:** Batch-specific mass-spectrometry testing for lead, mercury, arsenic and cadmium is the control that directly addresses the highest-evidence hazard, heavy-metal contamination of Ayurvedic products.

* **Single-herb root preparations instead of metal-containing formulas:** Punarnava Mandura, bhasma and other calx preparations, unless independently assayed, carry a deliberate-metal route to heavy-metal exposure and the reported liver-injury and rash signals.

* **Marker-standardised extract:** Products stating boeravinone B or β-ecdysone content per dose mitigate the 345-fold batch variability that otherwise makes any dose meaningless and unpredictable in both directions.

* **Medication audit before initiation:** Screening for CYP3A4, CYP2D6 and CYP1A2 substrates, lithium, and diuretics is the only practical defence against the enzyme-inhibition interaction, which produces no warning symptoms.

* **Low starting dose with slow titration:** Protocols start at 1–2 g root powder or 250 mg extract daily for two weeks before increasing, which limits gastrointestinal intolerance and allows excessive diuresis to be detected before volume depletion develops.

* **Daily weight and two-week electrolyte check:** A fall greater than 1.5 kg in a week, or sodium below 135 mmol/L, signals excessive diuresis, catching fluid and electrolyte depletion before dizziness or falls occur.

* **Liver enzymes at baseline and eight weeks:** A rise above three times the upper limit of normal is the accepted stopping threshold, and addresses the documented drug-induced liver injury signal, which is otherwise silent until symptoms appear.

* **Suspension before surgery and during acute illness:** Stopping at least two weeks pre-operatively and during vomiting, diarrhoea or fever prevents compounded volume depletion and unpredictable anaesthetic drug clearance.
  
## Therapeutic Protocol

* **Classical Ayurvedic root preparations:** Dried root powder 3–6 g daily, or decoction 50–100 mL twice daily, per the Ayurvedic Pharmacopoeia of India. This is the approach used in the multi-modal chronic kidney disease protocol developed at J.S. Ayurveda College, Nadiad.

* **Standardised extract capsules:** The Western supplement format, typically 250–500 mg of concentrated root extract once or twice daily. Popularised by commercial botanical suppliers rather than any clinic, and unvalidated against the classical dose.

* **Animal-derived dose estimate:** Examine.com converts effective rodent doses of 200–400 mg/kg to a human-equivalent 32–64 mg/kg — roughly 2,200–4,300 mg for a 68 kg adult, well above typical capsule labelling and untested in people.

* **Competing approaches without a default:** Classical whole-plant decoction and standardised single-marker extract rest on different logics — full-spectrum synergy versus reproducible dosing — and neither has outperformed the other in any comparative human study.

* **Best time of day:** Morning and early afternoon, with or after food. Given the diuretic effect, doses after mid-afternoon risk night-time urination and disturbed sleep; food reduces gastrointestinal upset.

* **Half-life and exposure:** No human half-life exists. In rats, boeravinone B peaks near 40 ng/mL and is measurable for hours, indicating rapid clearance and poor absorption; phospholipid complexation roughly doubles peak levels.

* **Single versus split dosing:** Split dosing is the traditional and pharmacologically sensible choice — twice or three times daily. Low bioavailability and short apparent exposure make a single large dose unlikely to sustain any effect through the day.

* **Genetic polymorphisms influencing dose:** No punarnava pharmacogenetic study exists. Known CYP2D6 or CYP3A4 poor-metaboliser status is not a reason to change punarnava dose, but is a strong reason to reconsider concurrent prescription medicines.

* **Sex-based differences:** No study has reported dose or response by sex. Absent data, dose is scaled to body weight rather than sex, with the in-vitro oestrogen-receptor activity noted as an untested source of possible divergence.

* **Age-related considerations:** Adults over 65 warrant the lower end of every range and slower titration, because reduced kidney reserve, blunted thirst and multiple concurrent medicines convert the same diuresis into volume depletion and drug accumulation more readily.

* **Baseline biomarker levels:** Filtration rate, electrolytes, liver enzymes and fasting glucose define both who is likely to notice an effect and who has least margin for error. Abnormal baselines change the risk calculus more than the dose.

* **Pre-existing health conditions:** Heart failure, cirrhosis, diabetes and chronic kidney disease all alter fluid handling and drug clearance, so any of them shifts the protocol toward supervised use rather than self-directed titration.
  
## Discontinuation & Cycling

* **Intended duration:** Traditionally an episodic remedy for swelling and urinary complaints rather than a lifelong daily supplement, though its classification as a *rasayana* has driven modern continuous use. Ayurvedic clinical protocols typically run four to twelve weeks.

* **Withdrawal effects:** None documented. The most likely event on stopping is return of fluid retention in someone whose swelling had responded, and reversal of the diuretic effect within days; no dependence or rebound syndrome has been described.

* **Tapering:** Not required on pharmacological grounds. Anyone whose diuretic medication was reduced while taking punarnava should have the prescription dose reviewed before stopping, so that fluid overload does not re-emerge unnoticed.

* **Cycling:** No efficacy-preserving cycling schedule has been tested. A practical case for periodic breaks rests on cumulative heavy-metal exposure rather than tolerance — for example eight to twelve weeks on, four weeks off, with periodic testing.
  
## Sourcing and Quality

* **Correct plant part:** The Ayurvedic Pharmacopoeia specifies the root. Leaf and whole-plant material have different constituent profiles — leaves are richer in antioxidants, roots in rotenoids — so a product listing "aerial parts" is not equivalent to root.

* **Species authentication:** *Trianthema portulacastrum*, *Boerhavia verticillata* and related species are routine substitutes. Genetic barcoding of the ITS (internal transcribed spacer, a DNA region that differs between species) reliably separates true punarnava, so a stated botanical authentication method carries more weight than a common name alone.

* **Marker standardisation:** Boeravinone B and β-ecdysone are the accepted chromatographic markers. A product declaring a specific content of either is verifiable; one declaring only a ratio such as "10:1 extract" is not, and the ratio says nothing about active content.

* **Heavy metal and contaminant testing:** Batch testing for lead, mercury, arsenic and cadmium against pharmacopoeial elemental-impurity limits, plus pesticide residues, matters because punarnava is often wild-harvested from roadsides and disturbed ground where metal uptake is highest.

* **Third-party certification:** NSF, USP Verified, and Informed Choice are the relevant marks. Coverage of Ayurvedic single herbs is sparse, and ConsumerLab has never tested this category, so a manufacturer's own accredited-laboratory certificate is often the only available evidence.

* **Reputable suppliers:** Banyan Botanicals, Organic India and Himalaya Wellness publish batch documentation for punarnava products and are among the more transparent options; brand reputation nonetheless substitutes poorly for a batch-specific certificate of analysis.

* **Formulation choice:** Plain root powder and marker-standardised extracts are the two defensible formats. Mandura and bhasma preparations deliberately contain processed metals and should be treated as a different intervention with a different risk profile.
  
## Practical Considerations

* **Time to effect:** Increased urine output, if it occurs, appears within hours to days. No human study has demonstrated a measurable kidney, liver or glucose effect at any timepoint; Ayurvedic protocols assess response at four to twelve weeks.

* **Common pitfall — buying the wrong plant:** Substitution with *Trianthema portulacastrum* is widespread enough that a dedicated genetic test was developed for it. A product with no authentication statement has an appreciable chance of containing a different species entirely.

* **Common pitfall — extrapolating animal doses:** Rodent-effective doses convert to gram-scale human intakes far above typical capsule labelling. Taking a 250 mg capsule and expecting the published animal effects confuses a marketing dose with a tested one.

* **Common pitfall — stacking with prescription diuretics:** People already on furosemide or a thiazide often add punarnava expecting a gentle complement. The combination is where volume depletion, low sodium and dizziness actually occur.

* **Common pitfall — treating mandura formulas as herbal:** Punarnava Mandura contains a processed iron calx. Users seeking a plant supplement can take a metal preparation unknowingly, which is where the reported liver injury and rash signals arose.

* **Regulatory status:** In the United States punarnava is a dietary supplement under DSHEA (the 1994 law that exempts supplements from pre-market efficacy review), so no claim has been evaluated by the FDA. In India it is a regulated Ayurvedic drug under the Ministry of Ayush.

* **Cost and accessibility:** Neither expensive nor hard to obtain — root powder and capsules typically cost well under one US dollar per day and ship internationally. Verified, batch-tested material is the scarce commodity, not the herb itself.
  
## Interaction with Foundational Habits

* **Sleep:** Direct and potentially disruptive. The diuretic action produces night-time urination when dosing runs late; the practical measure is to take the final dose before mid-afternoon. No study has measured sleep architecture on punarnava, and the anti-inflammatory and calcium-channel-blocking constituents have no demonstrated sedative effect in humans.

* **Nutrition:** Direct and two-way. The leaves are eaten as a vegetable in India and the plant contains oxalic acid, [confirmed by metabolite profiling](https://pubmed.ncbi.nlm.nih.gov/19500634/) — relevant for anyone prone to calcium-oxalate stones. With mandura formulations, take vitamin C alongside and separate tea, coffee, calcium and antacids by two hours to preserve iron absorption.

* **Exercise:** Indirect and potentially blunting. Combined diuresis and sweat loss can reduce plasma volume, hurting endurance performance and heat tolerance; fluid and sodium replacement matters more than usual. A theoretical concern that rotenoid chemistry could impair mitochondrial function and training adaptation has never been tested in humans.

* **Stress management:** No demonstrated interaction. Traditional *rasayana* framing and animal anti-stress claims for β-ecdysone have not been examined in people, and no human study has measured cortisol, perceived stress, or autonomic function on punarnava, leaving it neutral with respect to stress physiology on present evidence.
  
## Monitoring Protocol & Defining Success

Baseline assessment establishes where kidney and liver function actually sit, because both are the organs punarnava is taken for and the organs where problems would first show. Baseline testing covers a metabolic panel with eGFR (estimated glomerular filtration rate — how fast the kidneys filter blood), serum creatinine, BUN (blood urea nitrogen, a waste product the kidneys clear), sodium and potassium, uACR (urine albumin-to-creatinine ratio, a measure of protein leaking into urine), a liver panel with ALT and AST (alanine and aspartate aminotransferase, enzymes released when liver cells are damaged), fasting glucose with HbA1c (glycated haemoglobin, average blood sugar over three months), seated and standing blood pressure, body weight, and a blood lead level. For ongoing monitoring, recheck electrolytes and weight at two weeks, the full panel at eight weeks, then every six months, with blood lead annually for continuous users.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| eGFR | ≥ 90 mL/min/1.73 m² | Core outcome the herb is taken for | Conventional labs flag only below 60; a drift from 95 to 75 is meaningful and invisible under standard reporting |
| Serum creatinine | 0.6–1.0 mg/dL (women), 0.8–1.2 (men) | Detects both benefit and injury | Rises with muscle mass and after heavy training; fasting sample, avoid intense exercise for 48 h |
| BUN | 10–16 mg/dL | Sensitive to volume depletion from diuresis | Conventional range extends to 20; rises with dehydration and high protein intake before it reflects kidney damage |
| Serum sodium | 137–142 mmol/L | Primary safety marker for excess diuresis | Below 135 mmol/L means stop; pair with body weight, which moves earlier than sodium |
| Serum potassium | 4.0–4.5 mmol/L | Distinguishes punarnava from loop diuretics | Conventional range 3.5–5.2; the traditional claim of potassium sparing has never been verified in humans |
| uACR | < 10 mg/g | Earliest signal of filtration-barrier change | Conventional threshold is 30 mg/g; first morning sample, avoid after exercise, fever or urinary infection |
| ALT | ≤ 20 U/L (women), ≤ 25 (men) | Detects the documented liver-injury signal | Conventional upper limits of 40–55 U/L are too permissive; above 3× upper limit means stop |
| AST | ≤ 25 U/L | Pairs with ALT to localise injury | Rises after intense exercise independently of the liver; sample 48 h after hard training |
| HbA1c | 4.8–5.4% | Tracks the animal-derived glucose claim | Falsely low with anaemia or recent blood loss, which matters when taking iron-containing mandura formulas |
| Fasting glucose | 75–90 mg/dL | Catches additive hypoglycaemia with drugs | 8–12 h fast; pair with fasting insulin if the goal is metabolic rather than renal |
| Blood pressure (seated and standing) | 110–125 / 70–80 mmHg | Detects excessive volume loss | Measure standing after 1 and 3 min; a systolic drop over 20 mmHg indicates volume depletion |
| Blood lead | < 1.0 µg/dL | Addresses the highest-evidence product risk | The CDC reference value is 3.5 µg/dL, but no threshold is known to be safe; annually for continuous users |
| Serum ferritin | 50–150 ng/mL | Only for mandura-type iron formulations | Acute-phase reactant — falsely high with inflammation; pair with C-reactive protein to interpret |

Qualitative markers worth tracking alongside laboratory values:

* Ankle, hand and facial swelling, ideally photographed at a fixed time of day
* Urine frequency and volume, and whether night-time waking to urinate has increased
* Dizziness or light-headedness on standing, which precedes measurable volume depletion
* Energy levels and exercise tolerance, especially in hot weather
* Appetite, nausea and stool consistency, the earliest signs of gastrointestinal intolerance
* Any new rash, itching or jaundice, which warrant immediate discontinuation
  
## Emerging Research

* **Multi-modal Ayurvedic protocol in chronic kidney disease:** [NCT02477163](https://clinicaltrials.gov/study/NCT02477163) enrolled 521 non-dialysis patients at P.D. Patel Ayurveda Hospital, Nadiad, using a punarnavadi decoction enema within a broader regimen; completed 2022, single-arm and unblinded, with creatinine and urea as endpoints.

* **Punarnava-containing polyherbal capsule in hepatitis B:** [NCT02899130](https://clinicaltrials.gov/study/NCT02899130) is the only quadruple-blind, placebo-controlled trial containing *Boerhaavia diffusa*, testing 80 inactive carriers for viral load change over 12 months. Status is unknown since 2017, and no results have been posted.

* **Punarnava in alcoholic liver disease:** [NCT03503708](https://clinicaltrials.gov/study/NCT03503708) planned a 40-participant single-arm study of a three-herb capsule containing *Boerhaavia diffusa* against liver enzymes over three months. Registered as not-yet-recruiting since 2018, illustrating how often such trials are announced but not run.

* **Rotenoids as isolated renal drug candidates:** [Cheng et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39880066/) showed boeravinone C acts through PPAR-α in diabetic kidney disease, and [Lan et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42510631/) identified PGK1 (phosphoglycerate kinase 1, a glucose-metabolism enzyme) as a boeravinone A target in acute kidney injury.

* **Analytical quality control:** [Chaudhary et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42077207/) established chromatographic pattern recognition capable of separating authentic from non-authentic Indian market samples. If adopted by suppliers, this addresses the batch-variability problem that currently makes dose-response work impossible.

* **Bioavailability engineering:** [Patel et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40334820/) surveys nanocarrier and phospholipid approaches to the herb's poor absorption. Success here would strengthen the case by making animal-scale exposures achievable; it would equally raise the toxicological stakes.

* **Research that could weaken the case — rotenoid toxicology:** No study has tested whether boeravinones share rotenone's mitochondrial complex I inhibition at achievable human exposures. A positive finding would reframe the entire benefit profile, and no group appears to be pursuing it.

* **Research that could weaken the case — herb-drug interaction:** The [in-vitro CYP inhibition finding](https://pubmed.ncbi.nlm.nih.gov/28942133/) has never been followed by a human interaction study. A clinical probe-drug study could either dismiss the concern or make punarnava unusable alongside common prescriptions.

* **Structural bias in research funding:** Nearly all punarnava research is funded through Indian government Ayurveda channels or by manufacturers of punarnava products. No commercial sponsor has a patent incentive to fund a definitive trial, and no insurer faces a cost difference large enough to favour it over generic diuretics.
  
## Conclusion

Punarnava is a root long used in Indian traditional medicine to shed excess fluid and to support the kidneys and liver. Its distinctive root compounds are genuinely active in the laboratory: they blunt inflammation, quench reactive molecules, and protect kidney and liver tissue in animals given toxic drugs. That animal record is unusually consistent across independent groups and several different kinds of injury.

The human record is not. No properly designed, blinded human study of the herb on its own has been published in a century of investigation. What human data exist come from small, unblinded studies of multi-herb traditional protocols, mostly conducted and reported by Ayurvedic teaching institutions, government Ayurveda research bodies, and manufacturers who sell the products being tested — parties whose standing depends on a favourable result. No commercial sponsor has a financial reason to fund large studies of an unpatentable plant, which shapes the evidence base that exists.

The clearest safety signals concern the product rather than the plant: Ayurvedic preparations are frequently contaminated with lead, mercury or arsenic, and the amount of active material in commercial punarnava varies enormously between batches. The root also slows several liver enzymes that clear common medicines. On present evidence punarnava is an active but unproven plant medicine whose largest practical uncertainty is what is actually in the bottle.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**